尘螨特异性皮下免疫治疗在变应性鼻炎患者中的远期疗效研究

娄鸿飞; 黄嫣然; 王成硕; 王向东; 赵岩; 曹飞飞; 张罗

doi:10.13201/j.issn.1001-1781.2018.21.006

尘螨特异性皮下免疫治疗在变应性鼻炎患者中的远期疗效研究

- 1. 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科(北京, 100730);
- 2. 鼻病研究北京市重点实验室北京市耳鼻咽喉科研究所;
- 3. 首都医科大学附属北京同仁医院变态(过敏)反应科
基金项目:
国家自然科学基金重点项目 (No:81630023)

国家自然科学基金青年基金项目 (No:81400444)

国家自然科学基金面上项目 (No:81470678)

国家自然科学基金重点国际合作研究项目 (No:81420108009)

北京市医院管理局人才培养“使命”计划 (No:SML20150203)

北京市医院管理局人才培养“青苗”计划 (No:QML20150202)

详细信息

通讯作者: 张罗, E-mail:dr.luozhang@139.com

中图分类号: R765.21

收稿日期: 2018-07-02

Long-term efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients

- 1 Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China;
- 2 Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology;
- 3 Department of Allergy, Beijing Tongren Hospital, Capital Medical University

More Information

Corresponding author: ZHANG Luo, E-mail: dr.luozhang@139.com

Received Date: 02 July 2018

摘要

摘要: 目的: 比较尘螨过敏的儿童和成人变应性鼻炎患者皮下免疫治疗的远期疗效。方法: 以48例尘螨过敏的变应性鼻炎患者为研究对象,接受3年标准化尘螨特异性皮下免疫治疗,治疗结束后随访2年。治疗前基线、治疗结束时(3年)和治疗结束后2年(5年)评价所有患者的鼻部症状总评分、症状药物综合评分和生活质量评分。记录尘螨特异性皮下免疫治疗过程中的不良反应,评价其安全性。结果: 15例儿童和33例成人变应性鼻炎患者完成了该研究。与基线相比,3年尘螨特异性皮下免疫治疗显著改善了儿童和成人患者的症状及生活质量,减少了对症治疗用药,并且疗效持续至免疫治疗结束后2年。儿童组的3年疗效和5年疗效均显著优于成人组。2组患者在免疫治疗中均未出现严重不良反应,局部不良反应发生率差异无统计学意义。结论: 尘螨过敏的变应性鼻炎患者经皮下免疫治疗3年后,症状明显改善,用药减少,生活质量提高,安全性良好,且免疫治疗停止后2年疗效仍然持续稳定。儿童的改善程度大于成人,疗效更加显著。
- 鼻炎 /
- 变应性 /
- 尘螨 /
- 皮下免疫治疗 /
- 远期疗效 /
- 儿童
Abstract: Objective: This study was aimed to compare the long-term effects of house dust mite (HDM) subcutaneous immunotherapy (SCIT) in a cohort of Chinese pediatric and adult patients with allergic rhinitis (AR).Method: Total of 48 AR patients received standardized HDM-SCIT for 3 years, and they received 3 years of standardized dust mite-specific subcutaneous immunotherapy, followed by 2 years after treatment. Prior to treatment (baseline) and at the end of the 3-year and 5-year treatment periods, all patients were evaluated for total nasal symptom scores (TNSS), total combined score (TCS; symptoms(nasal + ocular)+daily medication score), and rhinoconjunctivitis quality of life questionnaire(RQLQ). Safety of HDM-SCIT was assessed according to adverse events reported.Result: Fifteen pediatric and 33 adult AR patients completed the study. HDM-SCIT significantly improved symptoms and RQLQ scores at the 3 rd year and 5th year in both children and adults. Superior efficacy was observed at the 3-year and 5-year timepoints in children compared to adults. The safety of HDM-SCIT was comparable in children and adults with AR.Conclusion: A 3-year course of HDM-SCIT is an effective, safe and sustainable long-term treatment in both pediatric patients and adults with AR, although children appear to achieve better long-term efficacy compared to the adults.
- rhinitis /
- allergic /
- house dust mite /
- subcutaneous immunotherapy /
- long-term efficacy /
- children

HTML全文

参考文献(24)

[1]	ZHANG L, HAN D, HUANG D, et al.Prevalence of self-reported allergic rhinitis in eleven major cities in China[J].Int Arch Allergy Immunol, 2009, 149:47-57.
[2]	WANG X D, ZHENG M, LOU H F, et al.An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005to 2011[J].Allergy, 2016, 71:1170-1180.
[3]	LOU H F, MA S, ZHAO Y, et al.Sensitization patterns and minimum screening panels for aeroallergens in self-reported allergic rhinitis in China[J].Sci Rep, 2017, 7:9286-9288.
[4]	NOON L.Prophylactic inoculations against hay fever[J].Lancet, 1911, 1:1572-1573.
[5]	DURHAM S R, PENAGOS M.Sublingual or subcutaneous immunotherapy for allergic rhinitis[J]?J Allergy Clin Immunol, 2016, 137:339-349.
[6]	BOUSQUET J, KHALTAEV N, CRUZ A A, et al.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008update (in collaboration with the World Health Organization, GA (2) LEN and AllerGen)[J].Allergy, 2008, 63:8-160.
[7]	ZHANG L, WANG C, HAN D, et al.Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis[J].Int Arch Allergy Immunol, 2009, 148:161-169.
[8]	OKUBO K, MASUYAMA K, IMAI T, et al.Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis[J].J Allergy Clin Immunol, 2017, 139:1840-1848.
[9]	KIM H, WASERMAN S, HÉBERT J, et al.Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis[J].Allergy Asthma Clin Immunol, 2014, 10:1-9.
[10]	ZIMMER A, BOULEY J, LE MIGNON M, et al.Aregulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy[J].J Allergy Clin Immunol, 2012, 129:1020-1030.
[11]	魏萍, 寇巍, 姚红兵.儿童变应性鼻炎伴哮喘患病率的Meta分析[J].临床耳鼻咽喉头颈外科杂志, 2016, 30 (9):698-701.
[12]	ENG P A, BORER-REINHOLD M, HEIJNEN I A, et al.Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood[J].Allergy, 2006, 61:198-201.
[13]	KARAKOC-AYDINER E, EIFAN A O, BARIS S, et al.Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis:a 3-year prospective randomized controlled trial[J].J Investig Allergol Clin Immunol, 2015, 25:334-336.
[14]	SAHIN E, DIZDAR D, DINC M E, et al.Long-term effects of allergen-specific subcutaneous immunotherapy for house dust mite induced allergic rhinitis[J].JLaryngol Otol, 2017, 131:997-1001.
[15]	杨钦泰.变应性鼻炎治疗的三部曲"脱离、脱敏、脱症"[J].临床耳鼻咽喉头颈外科杂志, 2017, 31 (1):3-5.
[16]	OKAMOTO Y, FUJIEDA S, OKANO M, et al.House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis[J].Allergy, 2017, 72:435-443.
[17]	HAN D H, CHOI Y S, LEE J E, et al.Clinical efficacy of sublingual immunotherapy in pediatric patients with allergic rhinitis sensitized to house dust mites:comparison to adult patients[J].Acta Otolaryngol, 2012, 132:S88-S93.
[18]	SOH J Y, THALAYASINGAM M, ONG S, et al.Sublingual immunotherapy in patients with house dust mite allergic rhinitis:prospective study of clinical outcomes over a two-year period[J].J Laryngol Otol, 2016, 130:272-277.
[19]	王成硕, 王向东, 张伟, 等.变应性鼻炎屋尘螨变应原皮下免疫治疗的远期疗效研究[J].中华耳鼻咽喉头颈外科杂志, 2012, 47 (10):804-808.
[20]	LAI X, LI J, XIAO X, et al.Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations[J].Int Arch Allergy Immunol, 2013, 160:37-46.
[21]	CALDERON M A, ALVES B, JACOBSON M, et al.Allergen injection immunotherapy for seasonal allergic rhinitis[J].Cochrane Datab Systematic Rev, 2007, 5:CD001936.
[22]	MORTUAIRE G, MICHEL J, PAPON J F, et al.Specific immunotherapy in allergic rhinitis[J].Eur Ann Otorhinolaryngol Head Neck Dis, 2017, 134:253-258.
[23]	SHAMJI M H, KAPPEN J H, AKDIS M, et al.Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma:an EAACI Position Paper[J].Allergy, 2017, 72:1156-1173.
[24]	STELMACH I, SOBOCINSKA A, MAJAK P, et al.Comparison of the long-term efficacy of 3-and 5-year house dust mite allergen immunotherapy[J].Ann Allergy Asthma Immunol, 2012, 109:274-278.